MAPT and Alzheimer disease: There is evidence to suggest that in tauopathies, the pathological aggregation of tau can be primary pathogenic e.g. in frontotemporal lobe dementia (FTLD-17) or secondary pathogenic e.g. to Aβ-aggregation in AD [21].